After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes

Last month, the FDA approved CellTrans’ Lantidra as the first cellular therapy for Type 1 diabetes. The next day, Eli Lilly agreed to pay more than $300 million for Sigilon Therapeutics, with whom it is co-developing a cell therapy for the autoimmune illness. And these announcements came on the heels of new data presented by Vertex and Sernova for their respective cell therapies for T1D. Needless to say, this space is hot—but experts say challenges remain.